Your browser doesn't support javascript.
Quantity of IgG response to SARS-CoV-2 spike glycoprotein predicts pulmonary recovery from COVID-19.
Nairz, Manfred; Sahanic, Sabina; Pizzini, Alex; Böhm, Anna; Tymoszuk, Piotr; Mitterstiller, Anna-Maria; von Raffay, Laura; Grubwieser, Philipp; Bellmann-Weiler, Rosa; Koppelstätter, Sabine; Schroll, Andrea; Haschka, David; Zimmermann, Martina; Blunder, Silvia; Trattnig, Kristina; Naschberger, Helene; Klotz, Werner; Theurl, Igor; Petzer, Verena; Gehrer, Clemens; Mindur, John E; Luger, Anna; Schwabl, Christoph; Widmann, Gerlig; Weiss, Günter; Löffler-Ragg, Judith; Tancevski, Ivan; Sonnweber, Thomas.
  • Nairz M; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria. manfred.nairz@i-med.ac.at.
  • Sahanic S; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Pizzini A; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Böhm A; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Tymoszuk P; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Mitterstiller AM; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • von Raffay L; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Grubwieser P; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Bellmann-Weiler R; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Koppelstätter S; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Schroll A; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Haschka D; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Zimmermann M; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Blunder S; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Trattnig K; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Naschberger H; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Klotz W; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Theurl I; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Petzer V; Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
  • Gehrer C; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Mindur JE; Repertoire Immune Medicines, Cambridge, MA, USA.
  • Luger A; Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.
  • Schwabl C; Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.
  • Widmann G; Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria.
  • Weiss G; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Löffler-Ragg J; Christian Doppler Laboratory for Iron Metabolism and Anemia Research, Medical University of Innsbruck, Innsbruck, Austria.
  • Tancevski I; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
  • Sonnweber T; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Sci Rep ; 12(1): 3677, 2022 03 07.
Article in English | MEDLINE | ID: covidwho-1730313
ABSTRACT
The CovILD study is a prospective, multicenter, observational cohort study to systematically follow up patients after coronavirus disease-2019 (COVID-19). We extensively evaluated 145 COVID-19 patients at 3 follow-up visits scheduled for 60, 100, and 180 days after initial confirmed diagnosis based on typical symptoms and a positive reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We employed comprehensive pulmonary function and laboratory tests, including serum concentrations of IgG against the viral spike (S) glycoprotein, and compared the results to clinical data and chest computed tomography (CT). We found that at the 60 day follow-up, 131 of 145 (90.3%) participants displayed S-specific serum IgG levels above the cut-off threshold. Notably, the highly elevated IgG levels against S glycoprotein positively correlated with biomarkers of immune activation and negatively correlated with pulmonary function and the extent of pulmonary CT abnormalities. Based on the association between serum S glycoprotein-specific IgG and clinical outcome, we generated an S-specific IgG-based recovery score that, when applied in the early convalescent phase, accurately predicted delayed pulmonary recovery after COVID-19. Therefore, we propose that S-specific IgG levels serve as a useful immunological surrogate marker for identifying at-risk individuals with persistent pulmonary injury who may require intensive follow-up care after COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Spike Glycoprotein, Coronavirus / COVID-19 / Lung Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-07489-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Spike Glycoprotein, Coronavirus / COVID-19 / Lung Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Female / Humans / Male / Middle aged Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-07489-6